Mar 19, 2018 20:05 pm UTC| Business
SAN DIEGO, March 19, 2018 -- aTyr Pharma, Inc. (Nasdaq:LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced operating...
ATA Reports Financial Results for Three- and Nine-Month Transition Periods Ended December 31, 2017
Mar 19, 2018 20:05 pm UTC| Business
BEIJING, March 19, 2018 -- ATA Inc. ("ATA" or the "Company") (Nasdaq:ATAI), a leading provider of advanced testing technologies and testing-related services in China, today announced preliminary unaudited financial...
T2 Biosystems to Present at the 17th Annual Needham Healthcare Conference
Mar 19, 2018 20:05 pm UTC| Business
LEXINGTON, Mass., March 19, 2018 -- T2 Biosystems, Inc. (NASDAQ:TTOO) an emerging leader in the development and commercialization of innovative medical diagnostic products for critical unmet needs in healthcare, today...
Mar 19, 2018 20:05 pm UTC| Business
SANTA MONICA, Calif., March 19, 2018 -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ:OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions, announced today that Roger Crystal,...
Mar 19, 2018 20:05 pm UTC| Business
Five Posters Highlighting Selinexor Data, Including in Combinations with Zejula® (niraparib) in Ovarian Cancer and Velcade® (bortezomib) in Neuroblastoma Two Posters Featuring Eltanexor Data in Prostate Cancer and AML;...
Delcath to Present at Oppenheimer 28th Annual Healthcare Conference
Mar 19, 2018 20:05 pm UTC| Business
NEW YORK, March 19, 2018 -- Delcath Systems, Inc. (OTCQB:DCTH), an interventional oncology Company focused on the treatment of primary and metastatic liver cancers, announces that Jennifer K. Simpson, Ph.D., MSN, CRNP,...
HealthEquity Reports Fourth Quarter and Fiscal Year Ended January 31, 2018 Financial Results
Mar 19, 2018 20:04 pm UTC| Business
Highlights of the fiscal year include: Revenue of $229.5 million, an increase of 29% compared to FY17.Net income of $47.4 million, an increase of 80% compared to FY17.Net income per diluted share of $0.77, compared to...